Posted on Sep 8, 2021, 12:33 PM
“A jewel” at 1.9 billion dollars, Sanofi has just bought the American biotech Kadmon. A definitive merger agreement with the French giant has been concluded, a purchase which is in line with its desire to “continue to grow its General Medicine business”. Kadmon indeed brings with it several promising drugs in the treatment of cancer or immune diseases.
1) Kadmon has an innovative treatment for transplant patients
Kadmon had its first success with the authorization by the US health agency on July 16 of belumosudil, sold under the brand Rezurock. It is the “first drug in its pharmacotherapeutic class indicated for the treatment of chronic graft-versus-host disease in adults and children from 12 years of age, after the failure of at least two previous systemic treatment lines. “
Biotech is also currently testing this drug against multiple sclerosis. A phase II clinical trial has been launched to assess its efficacy against this disease and its safety. The lab hopes Rezurock will bring similar results in the face of this difficult-to-treat disease, as multiple sclerosis shares similarities with the problems faced by transplant patients.
2) Biotech is pursuing several avenues in immuno-oncology
Kadmon is currently working on several drugs to treat cancer with immunotherapy. In particular, it launched a phase I trial to test KD033 to treat severe tumors (metastatic or locally advanced). It also has several molecules in preclinical development in immuno-oncology, against fibrosis and against autoimmune diseases.
3) The young company is not yet profitable
Kadmon is in the midst of research and development of its products, and so far has posted negative financial results. At the end of June 2021, it recorded a loss of 32 million dollars in the second quarter of 2021 and 59.4 billion for the first half, up compared to the same periods in 2020. Listed on October 26, 2020 at a level of 3 , 50 dollars, it is currently above 5 dollars.